Witold Zatoński

Witold Zatoński

Auto-generated profile, based on publicly available information

Witold Zatoński

Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial, Cancer Centre and Institute of Oncology, Warsaw, Poland; European Health Inequalities Observatory, Institute of Rural Health, Lublin, Poland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 1998 in BMJ
Verified
Journal Article
Closed access
PDF file
WZWitold A Zatonski
Witold A Zatonski
AMAnthony J McMichael
Anthony J McMichael
JPJohn W Powles
John W Powles
Objective: To investigate the reasons for the decline in deaths attributed to ischaemic heart disease in Poland since 1991 after two decades of rising rates. Design: Recent changes in mortality were measured as percentage deviations in 1994 from rates predicted by extrapolation of sex and age specific death rates for 1980-91 for diseases of the circulatory system and selected other categories. Available data on national and household food availability, alcohol consumption, cigarette smoking, socioeconomic indices, and medical services over time were reviewed. Main outcome measures: Age specific and age standardised rates of death attributed to ischaemic heart disease and related causes. Results: The change in trend in mortality attributed to diseases of the circulatory system was similar in men and women and most marked (>20%) in early middle age. For ages 45 to 64 the decrease was greatest for deaths attributed to ischaemic heart disease and atherosclerosis (around 25%) and less for stroke (<10%). For most of the potentially explanatory variables considered, there were no corresponding changes in trend. However, between 1986-90 and 1994 there was a marked switch from animal fats (estimated availability down 23%) to vegetable fats (up 48%) and increased imports of fruit. Conclusion: Reporting biases are unlikely to have exaggerated the true fall in ischaemic heart disease; neither is it likely to be mainly due to changes in smoking, drinking, stress, or medical care. Changes in type of dietary fat and increased supplies of fresh fruit and vegetables seem to be the best candidates. Among former socialist countries Poland has undergone unusually rapid social and economic changes since 1988-9, including aspects of diet Mortality from heart disease declined sharply during 1991-4 after long term increases; mortality from stroke declined less strongly This study investigated what has changed in Poland to reduce the risks of fatal events in people with established ischaemic heart disease Candidate dietary explanations were the substitution of unsaturated for saturated fats and increased consumption of fresh fruit and vegetables

3 January 2008 in BMC Public Health
Verified
Journal Article
Open access
PDF file
JTJochen René Thyrian
Jochen René Thyrian
DPDemosthenes Panagiotakos
Demosthenes Panagiotakos
EPEvangelos Polychronopoulos
Evangelos Polychronopoulos
RWRobert West
Robert West
WZWitold Zatonski
Witold Zatonski
UJUlrich John
Ulrich John
Smoking prevalence differs significantly across Europe. In addition, there are considerable differences in tobacco control activities across European countries. The relationship between prevalence and policy is under-researched. The present analysis examines the motivation to change smoking behaviour across 5 different European countries that differ considerably in their tobacco control activities. A population-based, representative survey of 1750 smokers, aged 16–59, from 5 different European countries (Germany, Greece, Poland, Sweden, UK) was used. Demographic variables, smoking status and the motivation to stop smoking were assessed. Motivation was assessed as, first, intending to quit (using the stages of change plus a modified stage for Precontemplation), and second, the desire to quit. The majority of smokers want to stop smoking (73.5%), while only 35.0% want to stop definitely. Across countries, 10.2% definitely do not want to stop. Most of the smokers can be categorised in the Precontemplation stage (between 62.6% and 77.7% depending on the country), one of the stages of change categories. The relationship between the stages of change and the country under examination is statistically significant (chi-square = 43.466, p < 0.001). In countries with a high level of tobacco control, the proportion of people in Precontemplation is lower than in countries with low tobacco control activity. There are differences in the stages of change between the countries under examination. However, the categorisation of the countries into low, medium and high tobacco control activity used in this analysis does not explain these differences. Most smokers want to stop smoking, but a high proportion cannot indicate a time-frame when this is going to happen. Tobacco control efforts or other kinds of support might encourage these smokers to actually try to stop. Longitudinal studies at the population level are needed to assess, relate or monitor tobacco control activities and the intention to stop.

27 November 2006 in Tobacco Control
Verified
Journal Article
Closed access
PDF file
WZWitold Zatonski
Witold Zatonski
MCMagdalena Cedzynska
Magdalena Cedzynska
PTPiotr Tutka
Piotr Tutka
RWRobert West
Robert West
Objectives:Cytisine (Tabex) has been licensed in Eastern Europe as an aid to smoking cessation for 40 years. Cytisine is a partial agonist with high affinity binding to the α4β2 nicotinic acetylcholine receptor believed to be central to the rewarding effect of nicotine. There is insufficient information on effectiveness to warrant licensing by modern standards. To assess whether full-scale controlled trials are warranted, this study sought to obtain an estimate of the 12-month continuous abstinence rates of smokers using cytisine with minimal behavioural support.Design:An uncontrolled, open-label trial.Setting:A smokers’ clinic in an oncology centre in Warsaw, Poland.Subjects:436 consecutive attendees of the smokers’ clinic of whom 191 were male. The mean dependence score (Fagerstrom Test for Nicotine Dependence) was 6.1.Intervention:The standard regimen of Tabex (cytisine) was used, involving 25 days of treatment with minimal behavioural support.Main outcome measure:Self-reported continuous abstinence for 12 months; with abstinence verified by carbon monoxide at the final follow up (after 12 months).Results:60 participants (13.8% of the total sample) were abstinent for 12 months. Of the 315 subjects, who had taken the drug, 49 (15.5%) stopped cytisine because of adverse effects (mostly gastric disturbances and nausea), although they were not serious. The frequency of the minor adverse effects, primarily gastric disturbance, was similar to that observed in previous studies with the drug.Conclusions:The long-term abstinence rates were similar to those observed in smokers receiving nicotine replacement therapy. Full-scale randomised trials of cytisine (Tabex), conducted to the standards required by regulatory authorities, are warranted.

1 March 2012 in Public Health
Verified
Journal Article
Closed access
WZW.A. Zatonski
W.A. Zatonski
NBN. Bhala
N. Bhala


5 April 2007 in BMC Cancer
Verified
Journal Article
Open access
PDF file
MGMontserrat Garcia-Closas
Montserrat Garcia-Closas
LBLouise A Brinton
Louise A Brinton
JLJolanta Lissowska
Jolanta Lissowska
DRDouglas Richesson
Douglas Richesson
MSMark E Sherman
Mark E Sherman
SCStephen J Chanock
Stephen J Chanock
The sex hormone-binding globulin (SHBG) is a carrier protein that modulates the bio-availability of serum sex steroid hormones, which may be involved in ovarian cancer. We evaluated whether common genetic variation in SHBG and its 3' neighbor ATP1B2, in linkage disequilibrium, is associated with the risk of epithelial ovarian cancer. The study population included 264 women with ovarian carcinoma and 625 controls participating in a population-based case-control study in Poland. Five common single nucleotide polymorphisms (SNPs) in SHGB and five in ATP1B2 were selected to capture most common variation in this region. None of the SNPs evaluated was significantly associated with ovarian cancer risk, including the putative functional SNPs SHBG D356N (rs6259) and -67G>A 5'UTR (rs1799941). However, our data were consistent with a decreased ovarian cancer risk associated with the variant alleles for these two SNPs, which have been previously associated with increased circulating levels of SHBG. These data do not support a substantial association between common genetic variation in SHBG and ovarian cancer risk.